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Abstract: Pancreatic enzyme replacement therapy (PERT) is the only treatment for 
malabsorption in cystic ﬁ  brosis (CF) caused by pancreatic insufﬁ  ciency (PI). PI occurs in 
approximately 85% of patients with CF. PERT overcomes some, but not all the signs and 
symptoms of malabsorption. Clinical parameters such as growth, abdominal pain, diarrhea 
and gassiness, commonly used to adjust PERT dosing, are shown not to be good indicators of 
their effectiveness. The FDA does not provide oversight of preparations of pancreatic enzymes 
consistent with the oversight it provides for all other drugs. The FDA intends to rectify this 
situation. Measures of the effectiveness of PERT are limited to the coefﬁ  cient of fat absorption, 
a difﬁ  cult and unpleasant exercise for patients.
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Introduction
Malnutrition is a common ﬁ  nding in people who have cystic ﬁ  brosis (CF) and 
malnutrition correlates with poor outcomes. Malnutrition occurs because of inadequate 
intake, increased losses, malabsorption of nutrients, or increased requirements. All of 
these occur in people who have CF; however, the most prominent cause of malnutri-
tion is malabsorption. There are many possible causes for malabsorption, including 
dysfunction of small bowel or liver and bacterial overgrowth, nevertheless, exocrine 
pancreatic insufﬁ  ciency is the most important cause in CF. Provision of pancreatic 
enzymes improves malabsorption, but does not return the absorptive function of the 
gastrointestinal tract to normal. Although there are many possible explanations, the 
focus of this article is on pancreatic enzyme replacements in cystic ﬁ  brosis.
Pancreatic enzyme development
Currently, all available pancreatic enzyme replacements for therapy (PERT) are porcine 
in origin. The ﬁ  rst formulations were powders obtained by freeze drying hog pancrease 
and administered as the crude product or after some extraction and puriﬁ  cation. They 
improved fat absorption, but much of the enzyme was inactivated in the acid-pepsin 
containing milieu of the stomach. To prevent inactivation of enzymes by acid, bicar-
bonate was administered with the enzyme or medication that suppressed acid was 
prescribed. Whether decreasing acid improved the efﬁ  cacy of the preparations is not 
clear (Ng and Jones 2008). Enteric coated enzymes were next developed. The coating 
protected the enzymes so they were resistant to acid. This allowed delivery of the 
intact enzyme to the duodenum and improved efﬁ  cacy, but did not completely prevent 
malabsorption. There are several possible reasons, products may deteriorate while on 
the shelf, activity of the crude extracts may vary, other proteins or substances in the Therapeutics and Clinical Risk Management 2008:4(5) 1080
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products may inactivate the enzymes, the coated enzymes 
may not leave the stomach at the same time as gastric fat, 
the acid resistant coating may not dissolve, enzymes may not 
be released in the proximal intestine or patient speciﬁ  c fac-
tors such as gastric acidity, motility or interaction with other 
medications may exist. New nonporcine enzyme products 
are in clinical trials (Borowitz et al 2006). These products 
in which the lipase, protease, and amylase are produced and 
puriﬁ  ed independently take advantage of crystallization 
and cross-linking of proteins.
Pancrealipase is a substance containing principally lipase, 
amylase and protease obtained from the pancreas of the hog. 
Each mg contains not less than 24 USP units of lipase, not 
less than 100 USP units of amylase and not less than 100 USP 
units of protease. Units of lipase activity are based on the rate 
of hydrolysis of olive oil, those of protease activity on the rate 
of hydrolysis of casein and those of amylase activity on 
the rate of hydrolysis of starch. (Sweetman 2007).
Pancrelipase cannot be sold without a prescription. 
Generic products exist. However, generic products may not be 
as efﬁ  cacious as the named brands (Hendeles et al 1990).
In fact, there is a plethora of porcine based enzyme 
replacements from powders to minimicrospheres with 
alkalinizing components. An updated list of pancrelipase 
formulations is available (Medline Plus 2008). Speciﬁ  c 
information on these products is not available because it is 
guarded as proprietary. There are many studies that attempt to 
demonstrate and/or compare the efﬁ  cacy of different prepara-
tions. However, it is difﬁ  cult at best to interpret the whole 
of these studies with any logic because of uncertainty in the 
product contents and activities. Making this difﬁ  cult situation 
even worse is the fact that measures of treatment outcomes, 
including the gold standard, 72 hour coefﬁ  cient of fat absorp-
tion (CFA) (Borowitz et al 2005), are not reliable.
FDA oversight
In a 2004 (Department of Health and Human Services 2004) 
review of enzyme products, the FDA found inconsistencies 
in the formulation, composition, enzymatic activities, dosage, 
stability, bioavailability, and manufacturing processes of 
enzymes that could signiﬁ  cantly compromise the safety and 
effectiveness of the drugs. None of the enzyme products 
on the market have received FDA approval because the 
development and marketing of pancreatic enzymes pre-
date the 1938 passage of the FDA approval act. The FDA 
allowed these products to be grandfathered and to remain 
on the market because of their lifesaving beneﬁ  ts. However, 
the lack of quality and consistency is of such concern that 
the FDA required that all enzyme products achieve FDA 
approval by 2008. In October, 2007 the FDA issued an 
extension to 2010 if the manufacturers have investigational 
new drug applications on active status on or before April 28, 
2008 and have submitted new drug applications on or before 
April 28, 2009. This extension was granted to ensure the 
availability of exocrine pancreatic drug products during the 
additional time needed to obtain marketing approval (Depart-
ment of Health and Human Services 2007). As noted by the 
FDA, there is no oversight for pancrealipase as there is for 
other drugs and there is variability among the preparations. 
It is questionable if the FDA will be successful in gaining 
the control it desires over the current products on the mar-
ket because there is no incentive for manufacturers of these 
enzymes to meet FDA requirements. There is no likelihood 
that the FDA would withdraw all pancreatic enzymes from 
the market because of the hardship and negative impact on the 
health of those with CF this would create. Representatives of 
the manufacturers, however, are clear that they want to meet 
the FDA requirements, but doing so will require considerable 
time and resources.
Indications for PERT
The most common reason for prescribing PERT is cystic 
fibrosis where approximately 85% of the patients are 
pancreatic insufﬁ  cient (PI) (Borowitz et al 2004). PERT is 
also prescribed for people who have Shwachman-Diamond 
Syndrome and PI that develops after an initially normal 
functioning pancreas is no longer capable of secretion, 
such as occurs after chronic pancreatitis from a variety of 
causes. Pancreatic enzymes are prescribed for pain control 
in chronic pancreatitis, but this use is controversial (Layer 
et al 2001).
Cystic ﬁ  brosis
Cystic fibrosis (CF) is an autosomal recessive disease 
affecting epithelial secretory tissues and manifested as pul-
monary and pancreatic dysfunction. The incidence of CF is 
1:3200 (Turcios 2005 ) live births among Caucasians. CF 
is caused by mutations in the gene that encodes the cystic 
fibrosis transmembrane conductance regulator (CFTR) 
protein. CFTR is an epithelial cell chloride channel that is 
highly conserved among species and has a wide tissue distri-
bution. It is expressed in many tissues including respiratory 
tract epithelia, sweat glands, pancreatic ducts, liver, colon, 
parotid gland, kidney, and seminiferous tubules. CFTR 
functions as a chloride channel and controls the regulation 
of other transport pathways. Mutations in the CFTR gene Therapeutics and Clinical Risk Management 2008:4(5) 1081
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cause cystic ﬁ  brosis and congenital bilateral aplasia of the 
vas deferens (OMIM 2008). Failure of the CFTR protein to 
function results in impaired chloride transport at the apical 
surface of epithelial cells and dysregulation of other trans-
porters such as chloride-coupled bicarbonate transport (Choi 
et al 2001) and sodium channel activity (Reddy et al 1999). 
Normal tissues secrete alkaline ﬂ  uids but mutant CFTR 
expressing tissues secrete acidic ﬂ  uids. Bicarbonate and pH 
affect mucin viscosity and bacterial binding. The result is low 
volume, high salt ﬂ  uid in the extracellular space. Although 
inspissation of zymogen may be the earliest pancreatic lesion 
in CF, mucous metaplasia follows (Tucker et al 2003). The 
viscous secretions cause luminal obstruction of ducts and that 
leads to acinar cell destruction, ﬁ  brosis and exocrine PI. The 
resulting PI is characterized by the decrease or absence of 
the exocrine pancreatic enzymes, amylase, proteases, lipase, 
colipase and phospholipases while salivary and brush border 
amylases are normal or elevated and lingual lipase levels are 
elevated (Guy-Crotte et al 1996). Pancreatic dysfunction is 
thought to be the main cause of severe malabsorption and 
poor nutrition in CF.
Pancreatic function in CF
Protein digestion begins in the stomach by acid hydrolysis 
and continues by brush border proteolytic enzymes. Similarly 
starch digestion can be achieved by salivary amylase and 
brush border oligosaccharidases. Protein and starch digestion 
are maintained even when virtually all pancreatic function 
is blocked. Fat malabsorption is the most important diges-
tive malfunction in pancreatic exocrine insufﬁ  ciency and 
is associated with abdominal pain, steatorrhea, ﬂ  atulence, 
diarrhea, and deﬁ  cits in energy and the fat soluble vitamins 
A, D, E, and K. Malabsorption causes growth failure and 
speciﬁ  c nutrient deﬁ  ciencies in children.
Nutrient delivery into the proximal small bowel is the 
most important stimulus of exocrine pancreatic secretion. 
Free fatty acids cause release of cholecystokinin and this 
stimulates pancreatic secretion (Guimbaud et al 1997). The 
pancreas has a high reserve capacity. Clinically signiﬁ  cant 
malabsorption is usually not detectable until 90%–95% 
of the secreting parenchyma is destroyed (DiMagno et al 
1973). When pancreatic enzyme output decreases by 
60%–90% it is likely that the site of maximal digestion 
and absorption shifts from the duodenum to more distal 
small bowel. Increased amounts of nutrients are delivered 
to the distal ileum and this causes disturbances in motor 
and secretory function of the upper gastrointestinal organs 
(Keller et al 1988; Layer et al 1997).
Enzyme dosing
Dosing of pancreatic enzymes is an inexact science. 
Treatment of malabsorption requires delivery of sufﬁ  cient 
enzyme activity into the duodenal lumen simultaneously with 
a meal. To achieve this, 40–60 U/mL of lipase activity are 
required. This is about 25,000 to 40,000 units/meal (Layer 
et al 1992) for adults.
For children, estimates for dosing of enzymes are 
based on lipase as well beginning with 1,000 lipase 
units/kg per meal for children less than 4 years of age and at 
500 lipase units/kg per meal for those older than 4 years of 
age (Borowitz 1995). Fewer enzymes per kilogram of body 
weight are recommended in older children because they tend 
to eat less fat per kilogram of body weight. For snacks half 
the dose is recommended since the food intake is less.
Infants may be given 2,000 to 4,000 units per 120 mL 
of infant formula or per breast feeding. The infant’s mouth 
should be swept after administration to prevent ulceration in 
the alkaline salivary environment (Borowitz et al 1995).
The daily dose for most patients is less than 10,000 units 
of lipase/kg per day or 6,000 units of lipase/kg per meal 
(Borowitz et al 1995; FitzSimmons et al 1999) to prevent 
ﬁ  brosing colonopathy.
For patients who cannot swallow capsules, delayed 
release capsules containing enteric coated microspheres or 
microtablets may be opened and the contents sprinkled on 
soft food that does not require chewing and has a low pH 
such as applesauce, gelatins, or pureed apricot, banana or 
sweet potatoes. Foods having a pH greater than 7.3, such as 
milk, custard or ice cream should be avoided as a vehicle 
for the sprinkled enzymes because the protective enteric 
coating can dissolve.
Pancrealipase tablets or capsules should not be crushed 
or chewed. If powder spills on skin, it should wash it off 
immediately. Care should be taken not to inhale the powder 
as it can be irritating to the respiratory tract.
Assessment of pancreatic function
The test that most accurately estimates pancreatic function 
is the secretin-pancreozymin stimulation test. This test 
requires duodenal intubation and collection of ﬂ  uid before 
and after intravenous hormonal stimulation of the pan-
creas (Cooper 1996). It is invasive, expensive and time 
consuming and although it deﬁ  nes PI it cannot be used to 
monitor the effectiveness of PERT. Similarly, serum immu-
noreactive trypsinogen, stool chymotrypsin or stool elastase 
assess pancreatic function, but cannot be used to monitor the 
effectiveness of PERT.Therapeutics and Clinical Risk Management 2008:4(5) 1082
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The most commonly performed test of pancreatic function 
is the 72-hour CFA. It does not discriminate among hepato-
biliary, mucosal or pancreatic causes for fat malabsorption. 
Intake must be carefully recorded, and many people ﬁ  nd the 
stool collection onerous. But, it is the only clinical available 
test that can be used to assess PERT (Borowitz et al 2006).
Clinical outcomes
Patients with PI take PERT to compensate for exocrine PI and 
improve nutrient absorption. PERT dosing is adjusted based 
on growth for children and on whether signs and symptoms 
of malabsorption are present or persist (Borowitz et al 1995, 
2002) on a given dose of enzymes. Signs and symptoms of 
malabsorption are usually self-reported and include frequent 
or loose bowel movements, excessive gas and stomach aches. 
Following is a discussion of growth, patient reported symp-
toms of malabsorption and PERT dosing in a cohort of 1,215 
patients with CF (Borowitz et al 2004; Baker et al 2005).
Growth is a necessary, but not sufﬁ  cient indicator of 
overall health in children. Patients with CF should have 
normal growth (Borowitz 2002) and poor clinical outcomes 
are associated with undernutrition in patients with CF 
(Kraemer et al 1978; Corey et al 1988; Dazell et al 1992; 
Kerem et al 1992; Pencharz and Durie 1993; Beker et al 
2001). Malabsorption secondary to PI is the most common 
reason for malnutrition in CF.
In a multicenter study of 1,215 patients with CF (Baker 
et al 2005) 93.4% of subjects were prescribed PERT and 
91.4% reported taking the enzymes. The reported adher-
ence to PERT is remarkable since typical adherence rates 
are about 50% for medications and lower for behaviorally 
demanding regimens (Haynes et al 2002). This study did not 
attempt to conﬁ  rm the reported adherence by more speciﬁ  c 
measures such as pill counting because simply asking 
patients about their adherence detects more than 50% of those 
with low adherence with a speciﬁ  city of 87% (Stephenson 
et al 1993).
Differences in growth among different age groups were 
identiﬁ  ed, but as a whole PI patients had better growth, and 
when growth was completed, healthier BMI than PS patients 
because of the higher frequency of obesity in PS patients. For 
patients 20 years of age 49.2% of the PS and 14.5% of the PI 
patients had a BMI  24.9. For patients 3 to 20 years of age, 
28.6 % of the PS and 18.1% of the PI patients had a BMI  
the 75th percentile for age. For patients less than 3 years 
of age, 24.1% of the PS and 14.2% of the PI patients had a 
weight-height ratio  the 75% for age. The UK data base of 
CF shows that 10.2 % of all patients with CF are overweight 
or obese (Kastner-Cole et al 2005). Of note, varying the dose 
of PERT from less than 500 units/kg/meal to 2,500 and more 
units/kg/meal did not correlate with growth.
Clinical symptoms
Abdominal pain occurred at least once a week in 9.6% of 
patients (PS or PI) with CF, approximately the same inci-
dence as the general population (Apley and Naish 1958; 
Hyams et al 1966; Rasquin-Weber et al 2000). No relation-
ship was found between abdominal pain and PERT intake 
from 500 to 2,500 lipase units/kg/meal, suggesting that 
pancreatic exocrine insufﬁ  ciency was not the main cause of 
abdominal pain and that increasing the dose of PERT would 
not alleviate these symptoms.
In the general population the incidence of constipation 
varies from about 15% in adults (Stewart 1999) to 34%–37% 
in children from birth to 12 years (Loening-Baucke 1998). In 
a chart review of 168 patients with CF ranging in age from 
less than 5 years to over 30 years, Rubinstein et al (1986) 
noted an incidence of constipation of 32%. Rubinstein et al 
did not differentiate between PI and PS patients. We observed 
a higher incidence of constipation in the PI patients, about 
1.5 times that of the PS patients. We did not observe an 
increase in constipation with increasing age (Baker et al 
2005). Further, there was no correlation between constipation 
and the PERT dose suggesting that constipation cannot 
be used as a marker for inappropriate PERT dosing. The 
commonly held belief that constipation is a consequence of 
high enzyme doses is not supported by these data.
About 1.6 times more patients with PI reported gassiness 
compared to PS. Our results showed that increasing PERT 
dose does not improve the patients’ subjective sense of gas-
siness. The prevalence of gassiness was strikingly similar to 
that of constipation and raised the suggestion that treatment 
for constipation be offered for gassy patients.
There was no signiﬁ  cant difference between PS and PI 
patients in the number of stools/day. In general, both PI and 
PS patients reported more stools per day than the non-CF 
population. Since diarrhea is the main clinical expression 
of malabsorption (Schmitz 2000) we expected to ﬁ  nd more 
patients with PI reporting a higher number of stools per day 
compared to PS. We also expected that in the PI patients 
increasing the PERT dose would be associated with fewer 
stools. In fact we found no difference between the PI and 
PS patients in the reported frequency of stools and PERT 
dosing had no effect on the reported number of stools. This 
suggests the number of stools per day is not a good clinical 
discriminator for making decisions about PERT dosing.Therapeutics and Clinical Risk Management 2008:4(5) 1083
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There are several reasons that outcome measures such as 
growth and symptoms such as abdominal pain, constipation, 
ﬂ  atulence and diarrhea may respond differently to PERT 
than anticipated. The patients may choose not to adhere to 
the prescribed medication, the enzymes may not be as effec-
tive as expected, or factors other than pancreatic exocrine 
insufﬁ  ciency may be causing the symptoms or contributing 
to them.
Conclusion
The treatment and monitoring of malnutrition in people with 
CF is a difﬁ  cult and inexact science. PI occurs in approxi-
mately 15% of patients with CF. PERT overcomes some, 
but not all the signs and symptoms of malabsorption and 
clinical parameters commonly used to adjust PERT dosing 
are shown not to be good discriminators. The FDA does not 
provide oversight of preparations of pancreatic enzymes 
consistent with the oversight it provides for all other drugs. 
The FDA is attempting to rectify this situation. Measures of 
the effectiveness of PERT are limited to CFA, a difﬁ  cult and 
unpleasant exercise for patients.
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